Prognostic impact of interval breast cancer detection in women with pT1a N0M0 breast cancer with HER2-positive status: Results from a multicentre population-based cancer registry study

A. Musolino, F. Falcini, A. Sikokis, D. Boggiani, A. Rimanti, B. Pellegrino, E. M. Silini, N. Campanini, E. Barbieri, C. Zamagni, R. Degli Esposti, L. Cortesi, G. Bisagni, L. Cavanna, A. Frassoldati, P. Sgargi, M. Michiara

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Background Although human epidermal growth factor receptor 2 (HER2) overexpression is associated with poor prognosis, patients (pts) with pT1a N0M0 breast cancers (BCs) have an excellent outcome across all subtypes. Interval cancers (ICs) have poorer survival than screen-detected (SD) tumours, and an association has been reported between ICs and HER2 overexpression. We aimed to determine, in a general population of pT1a N0M0 BCs with known screening status, whether HER2-positive ICs have a poorer outcome than HER2-positive SD cancers. Methods We evaluated all incident pT1a N0M0 BCs (n = 874) collected in the Emilia-Romagna region (Italy) from 2003 to 2009 and diagnosed in women aged 50–69. Pts unexposed to screening, with unknown HER2 status and/or treated with adjuvant trastuzumab were excluded from analysis. Results Sixty-one percent of the BCs were SD, whereas 19% were ICs. BCs with high histologic grade, hormone receptor–negative or HER2-positive status (odds ratio = 1.7; 95% confidence interval [CI]: 1.1–2.7) were more likely ICs. Median follow-up was 115 months. The 10-year invasive disease-free survival (iDFS) for HER2-positive ICs was lower than that for HER2-positive SD cancers: 75.0% (95% CI: 55.5%–94.5%) versus 93.8% (95% CI: 86.5%–100%). An interaction between ICs and HER2-positive status was found for poorer iDFS after adjusting for prognostic variables (HR = 5.3; 95% CI: 1.6–16.7). Conclusions IC detection may identify pts with HER2-positive pT1a N0M0 tumours in whom the rate of recurrence justifies consideration for conventional, anti-HER2, adjuvant treatment.

Original languageEnglish
Pages (from-to)10-20
Number of pages11
JournalEuropean Journal of Cancer
Volume88
DOIs
Publication statusAccepted/In press - Nov 23 2017

Fingerprint

Registries
Breast Neoplasms
Population
Neoplasms
Confidence Intervals
Disease-Free Survival
human ERBB2 protein
Italy
Odds Ratio
Hormones
Recurrence
Survival

Keywords

  • Breast cancer
  • Cancer registry
  • HER2-positive
  • Interval cancer
  • pT1a
  • Screening

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Prognostic impact of interval breast cancer detection in women with pT1a N0M0 breast cancer with HER2-positive status : Results from a multicentre population-based cancer registry study. / Musolino, A.; Falcini, F.; Sikokis, A.; Boggiani, D.; Rimanti, A.; Pellegrino, B.; Silini, E. M.; Campanini, N.; Barbieri, E.; Zamagni, C.; Degli Esposti, R.; Cortesi, L.; Bisagni, G.; Cavanna, L.; Frassoldati, A.; Sgargi, P.; Michiara, M.

In: European Journal of Cancer, Vol. 88, 23.11.2017, p. 10-20.

Research output: Contribution to journalArticle

Musolino, A, Falcini, F, Sikokis, A, Boggiani, D, Rimanti, A, Pellegrino, B, Silini, EM, Campanini, N, Barbieri, E, Zamagni, C, Degli Esposti, R, Cortesi, L, Bisagni, G, Cavanna, L, Frassoldati, A, Sgargi, P & Michiara, M 2017, 'Prognostic impact of interval breast cancer detection in women with pT1a N0M0 breast cancer with HER2-positive status: Results from a multicentre population-based cancer registry study', European Journal of Cancer, vol. 88, pp. 10-20. https://doi.org/10.1016/j.ejca.2017.10.024
Musolino, A. ; Falcini, F. ; Sikokis, A. ; Boggiani, D. ; Rimanti, A. ; Pellegrino, B. ; Silini, E. M. ; Campanini, N. ; Barbieri, E. ; Zamagni, C. ; Degli Esposti, R. ; Cortesi, L. ; Bisagni, G. ; Cavanna, L. ; Frassoldati, A. ; Sgargi, P. ; Michiara, M. / Prognostic impact of interval breast cancer detection in women with pT1a N0M0 breast cancer with HER2-positive status : Results from a multicentre population-based cancer registry study. In: European Journal of Cancer. 2017 ; Vol. 88. pp. 10-20.
@article{dbbc278811e24eceb76540ba48dac186,
title = "Prognostic impact of interval breast cancer detection in women with pT1a N0M0 breast cancer with HER2-positive status: Results from a multicentre population-based cancer registry study",
abstract = "Background Although human epidermal growth factor receptor 2 (HER2) overexpression is associated with poor prognosis, patients (pts) with pT1a N0M0 breast cancers (BCs) have an excellent outcome across all subtypes. Interval cancers (ICs) have poorer survival than screen-detected (SD) tumours, and an association has been reported between ICs and HER2 overexpression. We aimed to determine, in a general population of pT1a N0M0 BCs with known screening status, whether HER2-positive ICs have a poorer outcome than HER2-positive SD cancers. Methods We evaluated all incident pT1a N0M0 BCs (n = 874) collected in the Emilia-Romagna region (Italy) from 2003 to 2009 and diagnosed in women aged 50–69. Pts unexposed to screening, with unknown HER2 status and/or treated with adjuvant trastuzumab were excluded from analysis. Results Sixty-one percent of the BCs were SD, whereas 19{\%} were ICs. BCs with high histologic grade, hormone receptor–negative or HER2-positive status (odds ratio = 1.7; 95{\%} confidence interval [CI]: 1.1–2.7) were more likely ICs. Median follow-up was 115 months. The 10-year invasive disease-free survival (iDFS) for HER2-positive ICs was lower than that for HER2-positive SD cancers: 75.0{\%} (95{\%} CI: 55.5{\%}–94.5{\%}) versus 93.8{\%} (95{\%} CI: 86.5{\%}–100{\%}). An interaction between ICs and HER2-positive status was found for poorer iDFS after adjusting for prognostic variables (HR = 5.3; 95{\%} CI: 1.6–16.7). Conclusions IC detection may identify pts with HER2-positive pT1a N0M0 tumours in whom the rate of recurrence justifies consideration for conventional, anti-HER2, adjuvant treatment.",
keywords = "Breast cancer, Cancer registry, HER2-positive, Interval cancer, pT1a, Screening",
author = "A. Musolino and F. Falcini and A. Sikokis and D. Boggiani and A. Rimanti and B. Pellegrino and Silini, {E. M.} and N. Campanini and E. Barbieri and C. Zamagni and {Degli Esposti}, R. and L. Cortesi and G. Bisagni and L. Cavanna and A. Frassoldati and P. Sgargi and M. Michiara",
year = "2017",
month = "11",
day = "23",
doi = "10.1016/j.ejca.2017.10.024",
language = "English",
volume = "88",
pages = "10--20",
journal = "European Journal of Cancer",
issn = "0959-8049",
publisher = "Elsevier Ltd",

}

TY - JOUR

T1 - Prognostic impact of interval breast cancer detection in women with pT1a N0M0 breast cancer with HER2-positive status

T2 - Results from a multicentre population-based cancer registry study

AU - Musolino, A.

AU - Falcini, F.

AU - Sikokis, A.

AU - Boggiani, D.

AU - Rimanti, A.

AU - Pellegrino, B.

AU - Silini, E. M.

AU - Campanini, N.

AU - Barbieri, E.

AU - Zamagni, C.

AU - Degli Esposti, R.

AU - Cortesi, L.

AU - Bisagni, G.

AU - Cavanna, L.

AU - Frassoldati, A.

AU - Sgargi, P.

AU - Michiara, M.

PY - 2017/11/23

Y1 - 2017/11/23

N2 - Background Although human epidermal growth factor receptor 2 (HER2) overexpression is associated with poor prognosis, patients (pts) with pT1a N0M0 breast cancers (BCs) have an excellent outcome across all subtypes. Interval cancers (ICs) have poorer survival than screen-detected (SD) tumours, and an association has been reported between ICs and HER2 overexpression. We aimed to determine, in a general population of pT1a N0M0 BCs with known screening status, whether HER2-positive ICs have a poorer outcome than HER2-positive SD cancers. Methods We evaluated all incident pT1a N0M0 BCs (n = 874) collected in the Emilia-Romagna region (Italy) from 2003 to 2009 and diagnosed in women aged 50–69. Pts unexposed to screening, with unknown HER2 status and/or treated with adjuvant trastuzumab were excluded from analysis. Results Sixty-one percent of the BCs were SD, whereas 19% were ICs. BCs with high histologic grade, hormone receptor–negative or HER2-positive status (odds ratio = 1.7; 95% confidence interval [CI]: 1.1–2.7) were more likely ICs. Median follow-up was 115 months. The 10-year invasive disease-free survival (iDFS) for HER2-positive ICs was lower than that for HER2-positive SD cancers: 75.0% (95% CI: 55.5%–94.5%) versus 93.8% (95% CI: 86.5%–100%). An interaction between ICs and HER2-positive status was found for poorer iDFS after adjusting for prognostic variables (HR = 5.3; 95% CI: 1.6–16.7). Conclusions IC detection may identify pts with HER2-positive pT1a N0M0 tumours in whom the rate of recurrence justifies consideration for conventional, anti-HER2, adjuvant treatment.

AB - Background Although human epidermal growth factor receptor 2 (HER2) overexpression is associated with poor prognosis, patients (pts) with pT1a N0M0 breast cancers (BCs) have an excellent outcome across all subtypes. Interval cancers (ICs) have poorer survival than screen-detected (SD) tumours, and an association has been reported between ICs and HER2 overexpression. We aimed to determine, in a general population of pT1a N0M0 BCs with known screening status, whether HER2-positive ICs have a poorer outcome than HER2-positive SD cancers. Methods We evaluated all incident pT1a N0M0 BCs (n = 874) collected in the Emilia-Romagna region (Italy) from 2003 to 2009 and diagnosed in women aged 50–69. Pts unexposed to screening, with unknown HER2 status and/or treated with adjuvant trastuzumab were excluded from analysis. Results Sixty-one percent of the BCs were SD, whereas 19% were ICs. BCs with high histologic grade, hormone receptor–negative or HER2-positive status (odds ratio = 1.7; 95% confidence interval [CI]: 1.1–2.7) were more likely ICs. Median follow-up was 115 months. The 10-year invasive disease-free survival (iDFS) for HER2-positive ICs was lower than that for HER2-positive SD cancers: 75.0% (95% CI: 55.5%–94.5%) versus 93.8% (95% CI: 86.5%–100%). An interaction between ICs and HER2-positive status was found for poorer iDFS after adjusting for prognostic variables (HR = 5.3; 95% CI: 1.6–16.7). Conclusions IC detection may identify pts with HER2-positive pT1a N0M0 tumours in whom the rate of recurrence justifies consideration for conventional, anti-HER2, adjuvant treatment.

KW - Breast cancer

KW - Cancer registry

KW - HER2-positive

KW - Interval cancer

KW - pT1a

KW - Screening

UR - http://www.scopus.com/inward/record.url?scp=85034828054&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85034828054&partnerID=8YFLogxK

U2 - 10.1016/j.ejca.2017.10.024

DO - 10.1016/j.ejca.2017.10.024

M3 - Article

AN - SCOPUS:85034828054

VL - 88

SP - 10

EP - 20

JO - European Journal of Cancer

JF - European Journal of Cancer

SN - 0959-8049

ER -